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Hochu-ekki-to is a traditional herbal (Kampo) medicine that has been shown to be effective for
patients with Kikyo (delicate, easily fatigable, or hypersensitive) constitution. Previous case
reports have suggested that this herbal drug was effective for a certain subgroup of patients
with atopic dermatitis (AD). We aimed to evaluate the efficacy and safety of Hochu-ekki-to in
the long-term management of Kikyo patients with AD. In this multicenter, double blind,
randomized, placebo-controlled study, 91 Kikyo patients with AD were enrolled. Kikyo
condition was evaluated by a questionnaire scoring system. All patients continued their
ordinary treatments (topical steroids, topical tacrolimus, emollients or oral antihistamines)
before and after their protocol entry. Hochu-ekki-to or placebo was orally administered twice
daily for 24 weeks. The skin severity scores, total equivalent amount (TEA) of topical agents
used for AD treatment, prominent efficacy (cases with skin severity score=0at the end of the
study) rate and aggravated rate (more than 50% increase of TEA of topical agents from the
beginning of the study) were monitored and evaluated. Seventy-seven out of 91 enrolled
patients completed the 24-week treatment course (Hochu-ekki-to: n=37, placebo: n=40). The
TEA of topical agents (steroids and/or tacrolimus) was significantly (P<0.05) lower in the
Hochu-ekki-to group than in the placebo group, although the overall skin severity scores were
not statistically different. The prominent efficacy rate was 19% (7 of 37) in the Hochu-ekki-to
group and 5% (2 of 40) in the placebo group (P=0.06). The aggravated rate was significantly
(P<0.05) lowerintheHochu-ekki-togroup(3%; 1of37)thanintheplacebogroup(18%;7of39).
Only mild adverse events such as nausea and diarrhea were noted in both groups without
statistical difference. This placebo-controlled study demonstrates that Hochu-ekki-to is a useful
adjunct to conventional treatments for AD patients with Kikyo constitution. Use of Hochu-
ekki-to significantly reduces the dose of topical steroids and/or tacrolimus used for AD
treatment without aggravating AD.
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Introduction
Atopic dermatitis (AD) is a common, chronic, relapsing
eczematous skin disease with severe pruritus (1–3). The
incidence of AD appears to be increasing worldwide
(4,5), among which the percentage of adolescent- and
adult-type AD cases have also been increasing (6,7). The
precise pathogenesis of AD remains obscure and appears
complex. Topical steroids, topical tacrolimus, emollients
and oral antihistamines are used as the first-line
treatments in standard therapeutic guidelines for AD
(2,3,8). However, long-term application of topical ster-
oids could induce local adverse effects such as skin
atrophy and telangiectasia in a substantial number of
patients. Topical tacrolimus is a potent calcineurin
inhibitor that does not exhibit the hormonal adverse
effects associated with steroid therapy (9,10). The major
adverse effect in using topical tacrolimus is sensation of
skin burning or irritation after application (11). In
addition, the Food and Drug Administration (FDA)
has issued a public health advisory to inform healthcare
professionals and patients of a potential cancer risk by
the use of topical calcineurin inhibitors (http://www.fda.
gov/bbs/topics/ANSWERS/2005/ANS01343.html). This
concern is based on animal studies, case reports with a
small number of patients, or knowledge of the drug’s
action mechanism as immunosuppressant. According to
the FDA statement, it may take human studies of 10
years or longer to determine if the use of topical
calcineurin inhibitors is actually linked to cancer devel-
opment in human. These adverse effects and emotional
fear of long-term use of topical steroids and/or tacroli-
mus have caused topical steroid/tacrolimus phobia in
substantial number of patients with AD worldwide who
would like to avoid these topical agents if possible (12).
Moreover, clinical experience has shown that some of
AD patients are really refractory to these conven-
tional treatments, and indeed current AD therapeutic
guidelines recommend further intensive treatments such
as ultraviolet phototherapy or oral cyclosporine for such
patients (8).
In Japan, an alternative approach has been pursued to
treat these grave and/or refractory AD patients with
traditional herbal medicine such as Saiko-seikan-to,
Shohu-san, Oren-gedoku-to, Byakko-ka-ninjin-to, Tokaku-
joki-to, Unkei-to, Hochu-ekki-to and so on (13–33). These
prescriptions comprise several elemental herbs, combined
use of which is thought to help increase the treatment
effects and to diminish adverse reactions of each
individual herb. Among these prescriptions, formula
like Tokaku-joki-to are mainly aimed at eliminating
disease factors, whereas Hochu-ekki-to is aimed at
correcting abnormal homeostasis of the body. Each
prescription is selected individually according to the
pharmacological features and the constitution of each
patient. Hochu-ekki-to is composed of hot water extracts
from 10 species of herbal plants and is used for patients
with Kikyo constitution. Kikyo, or deficiency of Ki,i s
defined as delicate, easily fatigable, or hypersensitive
constitution typically associated with poor gastrointest-
inal functions, anorexia and night sweats (34). In
experiments using animal models, orally administered
Hochu-ekki-to exhibits various immunopharmacological
effects, especially anti-allergic properties. They include
suppression of serum IgE level and eosinophil infiltration
and improvement of dermatitis through controlling
Th1/Th2 balance possibly by inducing interferon g
production from intraepithelial lymphocytes (35–42).
In addition, Hochu-ekki-to helps to correct leukocytope-
nia of mice treated with anti-cancer agents and augments
the resistance against bacterial infections (43,44). These
results suggest that Hochu-ekki-to may be applicable
to the treatment of AD patients who have Kikyo
constitution. Although accumulating reports have
shown clinical efficacy of Hochu-ekki-to for AD patients
(13,15,17,20,21,25,27,29–33), no placebo-controlled study
has previously been conducted.
In this double-blind, placebo-controlled, randomized
clinical trial, we address a question of whether Hochu-
ekki-to has beneficial effects for Kikyo patients with AD
who have been treated with conventional modalities.
Methods
Hochu-ekki-to
Hochu-ekki-to fine granules of 7.5g contain hot water
extract (6.4g) from 10 species of medicinal plants
including Ginseng radix (4.0g), Atractylodis rhizoma
(4.0g), Astragali radix (4.0g), Angelicae radix (3.0g),
Zizyphi fructus (2.0g), Bupleuri radix (2.0g), Glycyrrhizae
radix (1.5g), Zingiberis rhizoma (0.5g), Cimicifugae
rhizoma (1.0g) and Aurantii nobilis Pericarpium (2.0g).
Assessment of Kikyo Condition
Kikyo condition was evaluated by a questionnaire scoring
system. As shown in Table 1, the scoring questionnaire
consisted of one ‘must have’ major sign (10 points) and
10 minor signs (2 points each). The patients who had the
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questionnaire were determined as Kikyo constitution.
Study Population
Patients (20–40 years of age) with Kikyo constitution
who fulfilled the diagnostic criteria of Japanese
Dermatological Association for AD were eligible for
this study. All the 91 AD patients enrolled had been
treated with topical steroids (mild, strong, or very strong
rank) and/or topical tacrolimus for more than 4 weeks
prior to the study, and were expected to continue
the same therapeutic regimen after the initiation of
the study. Patients were not eligible for the study if
they had been treated with only weak topical steroids
(without stronger topical steroids or tacrolimus), stron-
gest topical steroids, systemic steroids, oral suplatast
tosilate, allergen desensitization therapy, or any other
herbal medicines for <4 weeks prior to the study.
The study was approved by the responsible ethics
committee and was performed in accordance with the
Declaration of Helsinki and with Good Clinical Practice.
An informed witnessed consent was obtained from all
the patients.
Study Protocols
The study was performed in a multicenter, double blind,
randomized, placebo-controlled parallel-group design.
The patient number was randomly assigned a treatment
code of either Hochu-ekki-to or placebo using a block size
of 10 (5 per each group) by an independent controller
of the investigators. This code was concealed from
the investigators. During trial period, patients were
randomized to receive twice daily either Hochu-ekki-to
fine granules (Kracie Co., Ltd, Tokyo, Japan) or its
inactive placebo which were indistinguishable by its
appearance, odor and savor. The daily doses were 7.5g.
All patients continued their ordinary treatments such as
topical steroids (other than strongest class), topical
tacrolimus, emollients or oral anti-histamines. The skin
severity score, amounts of topical agents, adverse effects
and laboratory examination including serum IgE, lactate
dehydrogenase (LDH) or eosinophil counts were mon-
itored at pre (0-week)-, mid (12-week)- and post
(24-week)-treatment. The prominent efficacy (skin sever-
ity score=0 at the end of the study) rate and the
aggravated rate (more than 50% increase of amounts of
topical agents from the beginning of the study) were also
evaluated.
Assessment of Skin Severity Scores
The skin severity scores of AD patients were assessed
using the scoring system by the Atopic Dermatitis
Severity Evaluation Committee of Japanese Dermatolo-
gical Association (issued 2001). The skin severity scores
were composed of eruption intensity score and affected
skin area score. The body surface was divided into five
sites, namely head and neck, anterior trunk, posterior
trunk, upper extremities and lower extremities. The
eruption intensity and affected skin area were evaluated
and scored. Eruption intensity scores were evaluated
using three eruption items: (i) erythema/acute papules,
(ii) oozing/crusts and excoriation and (iii) lichenification/
chronic papules and nodules) in the severest area scored
from 0 to 3 points (0=absent, 1=mild, 2=moderate,
or 3=severe) for each item in each body site. The
affected skin area was also evaluated and scored in
each body site as 0, 1, 2, 3 points when affected skin
area was absent, less than one-third, one-third to
two-third, more than two-third of each body site,
respectively. Thus, the skin severity score ranges from 0
to 60 points.
Assessment of the Dosage of Topical Steroids and
Topical Tacrolimus
At each patient visit, the actual amounts used of topical
steroids and/or topical tacrolimus were measured by
weighing the returned ointment tubes from examinees.
The amount of topical agents (steroids and tacrolimus)
per day was expressed as total equivalent amount (TEA)
(gram arbitrary unit; gau) by multiplying potency
equivalent factors as follows; weak rank steroids= 1,
mild rank steroids= 2, strong rank steroids= 4, very
strong rank steroids= 8, tacrolimus= 4. Percent
change of TEA to that of the beginning of the study
Table 1. Questionnaire scoring system for Kikyo constitution
Items Signs and conditions Scores
Major sign
(must-have)
Easy fatigability or lack of perseverance 10
Susceptibility
to infections
Susceptible to cold 2
Delayed recovery from cold 2
Vulnerable to other infectious diseases
(herpes virus etc)
2
Susceptible to suppuration 2
Anorexia Recent very little eating 2
Appetite loss 2
Easily-becoming full stomach 2
Nahrungsverweigerung 2
Digestive
symptom
Diarrhea (laxity) 2
Others Easy drowsiness especially after meals 2
Total scores 30
Patients who have the major sign and earn 18 points or more in this
questionnaire scoring system are determined as Kikyo constitution.
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treatment using the following formula;
Percentage changes of TEA
¼
TEA at 12th or 24th week   Initial TEA
Initial TEA
  100 ð%Þ
Statistical Analysis
Statistical analysis was performed using SAS statistical
software (version 8.02; SAS Institute, Cary, NC) under
the Windows XP operating system. Data were expressed
as the means standard deviation (SD) or standard error
(SE). A P-value of <0.05 was considered to indicate
statistical significance. Treatment efficacy was analyzed
by comparing the difference between Hochu-ekki-to and
placebo control groups using unpaired Student’s t-test or
Fisher’s exact test.
Results
Patient Enrollment and/or Exclusion
In total, 91 patients were enrolled and randomized in this
trial from February to November 2002. Seven out of the
initial 91 enrolled patients were excluded from subsequent
analysis for the following reasons; agreement acquisition
violation (n=4), eligibility violations (n=2) and failure
to take trial medicine at all (n=1). Thus the number of
patients who actually received medication (hereafter
termed ‘full analysis set: FAS’ group) and who were
analyzed was 84 (Hochu-ekki-to: n=40, placebo: n=44).
Seventy-seven out of the 84 patients completed the
24-week treatment course (Fig. 1), including a patient
in whom TAE of topical agents could not be assessed
because of the insufficient descriptions on the item. There
were no statistically significant differences between
Hochu-ekki-to- and control groups in terms of age, sex,
physique, duration of AD morbidity, incidence of past-
or present history of other allergic or non-allergic
diseases, Kikyo score, skin severity score, initial TAE of
topical agents per day (Supplementary data 1). Two out
of the 7 dropped-out cases during the trial (One each in
placebo and Hochu-ekki-to group) were excluded because
of a significant aggravation of skin eruption and
occurrence of headache, respectively. Others were found
unfit for further analyses (dismissal of medication etc).
Clinical Efficacy of Hochu-ekki-to
The overall skin severity score gradually decreased as
examination went on and was slightly lower in Hochu-
ekki-to group (closed circle) than in placebo group (open
circle) at 24th week (Fig. 2). The TEA of topical agents
gradually increased in the placebo group during the trial
period, whereas such increase of TEA was minimal
to unchanged in the Hochu-ekki-to group. The percent
change of TEA at 24th week was significantly (P<0.05)
lower in the Hochu-ekki-to group (closed circle) than in
the placebo control group (open circle) (Fig. 3).
Since Hochu-ekki-to was thought to be a slow-acting
herbal medicine and the present trial was relatively long-
term, we wondered if a striking beneficial effect was
observed in a certain population of patients by long-term
use of Hochu-ekki-to. Therefore, we analyzed a promi-
nent efficacy rate, the rate of patients whose skin severity
Figure 2. The time course change of skin severity score during examina-
tion. Skin severity scores were assessed at pre-, mid (12-week)- and post
(24-week)-treatment in Hochu-ekki-to- (closed circle) and placebo group
(open circle). Data were expressed as the mean SD. There is no
significant difference between Hochu-ekki-to- and placebo groups.
Figure 1. The chart of case enrollment and exclusion. Among the 91
enrolled AD patients, 84 patients were medicated and 77 out of the
84 patients completed full term (for 24 weeks) of trial.
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efficacy rate was indeed moderately higher in the Hochu-
ekki-to group (19%; 7 of 37) than in the placebo group
(5%; 2 of 40), although there was not a significant
difference (P=0.06). Furthermore, the aggravated rate,
defined as ratio of patients whose TEA had increased
more than 50% at 24 weeks from the beginning of the
study, was significantly lower in the Hochu-ekki-to group
(3%; 1 of 37) than in the placebo group (18%; 7 of 39)
(P<0.05). There was no significant difference in the
serum IgE, LDH, or eosinophil counts in peripheral
blood in both groups (data not shown).
Adverse Events and Abnormal Laboratory Findings
The adverse events, including those of unclear causality
with treatment using tested agents, were observed in 13 of
40 patients (32.5%, total 33 events) in the Hochu-ekki-to
group and in 12 of 44 patients (27.3%, total 20 events) in
the placebo group. All the adverse events were moderate
symptoms such as nausea and diarrhea etc or slight
increase or decrease of laboratory data (Table 2).
Discussion
The present study demonstrates that 24-week oral
administration of Hochu-ekki-to has a substantial benefit
over placebo in the treatment of Kikyo patients with AD.
The administration of Hochu-ekki-to significantly reduces
dosage of topical steroids and/or tacrolimus, compared
with placebo, although there was no significant difference
in the mean skin severity scores between both groups.
These results indicate that the patients in the placebo
group need significantly more topical steroids and/or
tacrolimus in order to control their skin conditions. In
keeping with this notion, the post-treatment prominent
efficacy rate tends to be higher in the Hochu-ekki-to
group than in the placebo group. In contrast, the
aggravated rate was significantly lower in the Hochu-
ekki-to group than in the placebo group. It was surprising
that 19% of patients in the Hochu-ekki-to group were
devoid of skin eruption after the 24-week treatment.
Considering the long-term history of the majority of the
7 ‘eruption-free’ patients (10–34 years, mean SD:
21.9 8.0), this marked improvement would indicate the
beneficial effects of Hochu-ekki-to, as ‘spontaneous’
healing was not likely to take place in those severe AD
patients during the course of trial.
Hochu-ekki-to, however, did not seem to be effective for
all the AD patients in this trial. Individual difference of
intestinal flora has been proposed to be one of the major
reasons for such disparity of the efficiency of Kampo
therapy. It is because active components of orally
administered herbal drugs are known to be assimilated
through the intestinal mucosa under the influence of
the intestinal flora (45). Although we generally advise
patients to choose traditional Japanese diet in usual
Figure 3. The time course change of equivalent dosage of topical agent
during examination. The percent changes of TEA of topical agents were
assessed at pre-, mid (12-week)- and post (24-week)-treatment in Hochu-
ekki-to- (closed circle) and placebo group (open circle). Data were
expressed as the mean SE. The TEA of topical agents gradually
increased in the placebo group as trial went, while such increase was
minimal to unchanged in the Hochu-ekki-to group. *P<0.05.
Table 2. Adverse effects
The number of cases
with adverse effects
Adverse effects (the number of cases if not one), including those of unclear causality with treatment
using tested agents
Hochu-ekki-to
group
13/40 (32.5%) Symptoms: nausea (2), diarrhea (2), stomach discomfort (2), enlarged feeling of abdomen, epigastralgia,
anorexia, loose stools, right hypochondrium pain, malaise, dizziness, headache, light-headed feeling,
rhinitis, acne pustulosa, feverish thirstiness, dental caries.
Laboratory data: eosinophilia (3), GPT elevation, IgE elevation, BUN decline, serum K elevation.
Placebo-control
group
12/44 (27.3%) Symptoms: ovarian disorder (2), diarrhea, epigastric discomfort, anorexia, malaise, hives, insomnia,
feverish limbs.
Laboratory data: eosinophilia (4), LDH elevation (2), GOT elevation (2), g-GTP elevation, serum
total protein decline, hemoglobin decline.
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daily diet, we have avoided intensive intervention during
this trial period, assuming that such intervention could be
a considerable stress for certain patients and could
significantly influence their clinical course of skin
symptoms by increasing itch sensation etc. The clinical
action of Hochu-ekki-to appears to be rather mild and
limited; however, the present study clearly demonstrates
an add-on beneficial effect of this herbal drug over
the conventional treatments. Kampo herbal drugs are
broadly classified into two categories, immediate acting-
and slow acting ones. Since Hochu-ekki-to is considered
to work in the latter manner, supporting the inactive
Kikyo body to become warm and active. Thus, it needs to
be administered for a long time to be shown effective.
A long-term (for 24 weeks) administration was adopted
in our protocol design because of the relatively slow
acting profile of Hochu-ekki-to. The significant clinical
benefits indeed appeared at 24th week rather than 12th
week, as shown by the reduction of TEA of topical
agents and of the reduced aggravated rates.
Kampo herbal drugs are usually prescribed according
to patient’s Sho (constitution/condition) such as Yin
(negativity) and Yang (positivity) or Kyo (deficiency) and
Jitsu (fullness) and to target components to treat such as
Ki (energy, spirit and function), Ketsu (blood and organs)
and Sui (fluid), all of which are considered to be basic
components constituting human body. Hochu-ekki-to is
recommended to be used for Kikyo condition, a state of
functional deficiency. In our trial, only AD patients with
Kikyo constitution were selected eligible by using the
questionnaire scoring system. This selection may favor-
ably contribute to carve in relief of the clinical
significance of Hochu-ekki-to over placebo, thus it
remains to be tested if the herbal drug has such beneficial
effect on AD patients without Kikyo constitution.
Although considerable attention has been paid on
traditional herbal medicines as a treatment option for
AD (13–33), there are only a few reports examining their
efficacy in a randomized, double blind manner, as
reviewed by Armstrong and Ernst (46). Sheehan et al.
(47–49) have reported the usefulness of the composite
herbs of Zemaphyte in a randomized, double blind
cross-over trial, where it was shown that the Zemaphyte’s
composite herbs possess anti-inflammatory and anti-
congestive function (48). However, a subsequent trial by
Fung et al. (50) failed to confirm its superiority over
placebo. Although efficacies of herbal medicines are now
being recognized even outside the Asian countries (51),
there has been no report of double-blind, randomized
and placebo-controlled trial of herbal drugs as treatment
for AD other than Zemaphyte before the present study.
In conclusion, our results indicate that Hochu-ekki-to is
a useful adjunct to conventional treatments for Kikyo
patients with AD. We contend that it can reduce the
dosage of topical steroids and tacrolimus without
aggravating the clinical course of AD.
Supplementary Data
Supplementary data are available at eCAM online.
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